| Ticker Details |
Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company. It discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases.
|
| IPO Date: |
December 7, 2000 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$857.22M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.27 | 3.09%
|
| Avg Daily Range (30 D): |
$1.06 | 2.62%
|
| Avg Daily Range (90 D): |
$1.02 | 2.95%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1M |
| Avg Daily Volume (30 D): |
.23M |
| Avg Daily Volume (90 D): |
.27M |
| Trade Size |
| Avg Trade Size (Sh.): |
223 |
| Avg Trade Size (Sh.) (30 D): |
46 |
| Avg Trade Size (Sh.) (90 D): |
49 |
| Institutional Trades |
| Total Institutional Trades: |
1,982 |
| Avg Institutional Trade: |
$1.48M |
| Avg Institutional Trade (30 D): |
$2.22M |
| Avg Institutional Trade (90 D): |
$2.1M |
| Avg Institutional Trade Volume: |
.04M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.7M |
| Avg Closing Trade (30 D): |
$1.96M |
| Avg Closing Trade (90 D): |
$2.1M |
| Avg Closing Volume: |
57.25K |
|
|
| Financials |
| |
TTM |
Q2 2026 |
Q1 2026 |
|
Basic EPS
|
$17.83
|
$.93
|
$.47
|
|
Diluted EPS
|
$16.88
|
$.88
|
$.44
|
|
Revenue
|
$276.79M
|
$78.7M
|
$58.82M
|
|
Gross Profit
|
$252.95M
|
$70.18M
|
$54.21M
|
|
Net Income / Loss
|
$321.91M
|
$17.29M
|
$8.65M
|
|
Operating Income / Loss
|
$87.05M
|
$23.58M
|
$11.89M
|
|
Cost of Revenue
|
$23.84M
|
$8.53M
|
$4.61M
|
|
Net Cash Flow
|
$7.41M
|
$36.41M
|
$-16.17M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Jun 27, 2024
|
1:10
|
|
Jun 25, 2003
|
1:9
|
|
|
|
